Senaste uppdateringen :
19/11/2024
Analgetikum   Morphine sulfate  
injektion
Oral lösning Salvor
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Dimor F Brasilien
Duramorph Förenta Staterna
Infumorph Förenta Staterna
Miniject Morphine Storbritannien
Morphine Kanada
Morphine sulfate Lavoisier Frankrike
Hänvisningar   injektion   Hänvisningar : Morphine sulfate  
Typ Publikation
3 tidningen Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6 tidningen Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
8 tidningen Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER.
Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 368-371.
57 tidningen Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
58 tidningen Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
59 tidningen Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 tidningen Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
64 tidningen DiStefano JE, Outman WR.
Additional data on visual compatibility of foscarnet sodium with morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 1672.
65 tidningen Duafala ME, Kleinberg ML, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D.
Stability of morphine sulfate in infusion devices and containers for intravenous administration.
Am J Hosp Pharm 1990 ; 47: 143-146.
73 tidningen Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 tidningen Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 tidningen Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
86 tidningen Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA.
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration.
Am J Hosp Pharm 1994 ; 51: 2812-2815.
91 tidningen Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
93 tidningen Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99 tidningen Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
115 tidningen Nahata MC, Morosco RS, Hipple TF.
Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures.
Am J Hosp Pharm 1992 ; 49: 2785-2786.
116 tidningen Stiles ML, Tu YH, Allen LV Jr.
Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration.
Am J Hosp Pharm 1989 ; 46: 1404-1407.
117 tidningen Vecchio M, Walker SE, Iazzetta J, Hardy BG.
The stability of morphine intravenous infusion solutions.
Can J Hosp Pharm 1988 ; 41: 5-9.
119 tidningen Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH.
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices.
J Clin Pharm Ther 1994 ; 19: 361-369.
120 tidningen Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B.
Hydromorphone and morphine stability in portable infusion pump cassettes and minibags.
Can J Hosp Pharm 1988 ; 41: 177-182.
121 tidningen Walker SE, Iazzetta J, Lau DWC.
Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes.
Can J Hosp Pharm 1989 ; 42: 195-200.
122 tidningen Grassby PF, Hutchings L.
Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes.
Int J Pharm Pract 1993 ; 2: 39-43.
129 tidningen Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
169 tidningen Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 tidningen Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
199 tidningen Hassan E, Leslie J, Martir-Herrero ML.
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 2143-2145.
218 tidningen Vogt C, Ruggaber S.
Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection.
Am J Hosp Pharm 1993 ; 50: 2311.
220 tidningen Johnson CE, Christen C, Perez MM, Ma M.
Compatibility of bupivacaine hydrochloride and morphine sulfate.
Am J Health-Syst Pharm 1997 ; 54: 61-64.
221 tidningen Neels JT.
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 2149.
240 tidningen Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244 tidningen Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 tidningen Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 tidningen Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 tidningen Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
257 tidningen Hunt-Fugate AK, Hennessey CK, Kazarian CM.
Stability of fluconazole in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1186-1187.
266 tidningen Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
295 tidningen Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 tidningen Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 tidningen Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
314 tidningen Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
315 tidningen Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 tidningen Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
319 tidningen Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
334 tidningen Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 tidningen Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 tidningen Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 tidningen Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
340 tidningen Macias JM, Martin WJ, Lloyd CW.
Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation.
Am J Hosp Pharm 1985 ; 42: 1087-1094.
341 tidningen Baker DE, Yost GS, Craig VL, Campbell RK.
Compatibility of heparin sodium and morphine sulfate.
Am J Hosp Pharm 1985 ; 42: 1352-1355.
386 tidningen Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
398 tidningen Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
402 tidningen Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
404 tidningen Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299.
405 tidningen Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
406 tidningen Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820.
492 tidningen Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 tidningen Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
513 tidningen Xu QA, Trissel LA, Martinez JF.
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride.
Ann Pharmacotherapy 1996 ; 30: 756-761.
517 tidningen Letourneau M.
Visual compatibility of magnesium sulfate with narcotic analgesics.
Am J Hosp Pharm 1992 ; 49: 838-839.
519 tidningen Poggi GL.
Compatibility of morphine tartrate admixtures in polypropylene syringes.
Aust J Hosp Pharm 1991 ; 21: 316.
660 tidningen Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
813 tidningen Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
814 tidningen Johnson CE, VandenBussche HL, Chio CC, Jacobson PA.
Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration.
Am J Health-Syst Pharm 1999 ; 56: 164-169.
815 tidningen Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905 tidningen Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 tidningen Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
932 tidningen Hor MMS, Chan SY, Yow KL, Lim LY, Chan E, Ho PC.
Stability of morphine sulphate in saline under simulated patient administration conditions.
J Clin Pharm Ther 1997 ; 22: 405-410.
1020 tidningen Zuber DEL.
Compatibility of morphine sulfate injection and prochlorperazine injection.
Am J Hosp Pharm 1987 ; 44: 67.
1041 tidningen Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1057 tidningen Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 tidningen Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1079 tidningen Stevenson JG, Patriarca C.
Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes.
Am J Hosp Pharm 1985 ; 42: 2651.
1135 tidningen Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 tidningen Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1232 tidningen Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1276 tidningen Shiffman E, Walker SE, Yoon T, Yeung M.
Stability and compatibility of morphine with bupivacaine.
Can J Hosp Pharm 1998 ; 51: 110-116.
1315 tidningen Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1341 tidningen Deeks T, Davis S, Nash S.
Stability of an intrathecal morphine injection formulation.
Pharm J 1983 ; 230: 495-497.
1410 tidningen Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 tidningen Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1438 tidningen Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841.
1467 tidningen Sitaram BR, Tsui M, Rawicki HB, Lam S, Courage P, Sitaram M, Chapman CB.
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump.
Int J Pharm 1995 ; 118: 181-189.
1490 tidningen Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1492 tidningen LeBelle MJ, Savard C, Gagnon A.
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures.
Can J Hosp Pharm 1995 ; 48: 155-160.
1495 tidningen Nixon AR, O'Hare MCB, Chisakuta AM.
The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations.
Pharm J 1995 ; 254: 153-155.
1496 tidningen Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1512 Laboratorium Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1516 Laboratorium Ropivacaine (Naropeine®) - Summary of Product Characteristics
Mercury Pharmaceuticals Limited 2012
1603 tidningen Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 tidningen Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 tidningen Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 tidningen Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1665 tidningen Öster Svedberg K, McKenzie J, Larrivee-Elkins C.
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine.
J Clin Pharm Ther 2002 ; 21: 39-45.
1678 tidningen Sitaram BR, Tsui M, Rawicki HB, Lam S, Sitaram M.
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine.
Int J Pharm 1997 ; 153: 13-24.
1707 tidningen Trissel LA, Xu QA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 70-73.
1708 tidningen Xu QA, Trissel LA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 66-69.
1709 tidningen Trissel LA, Xu QA.
Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 62-65.
1713 tidningen Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 tidningen Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 tidningen Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 tidningen Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 tidningen Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1810 tidningen Lee G, Sabra K, Doyle N, Malley GO.
Stability of morphine sulphate in P.C.A.s.
EJHP 2003 ; 1:1-3.
1869 tidningen Hildebrand KR, Elsberry DD, Hassenbusch SJ.
Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system.
J Pain Symptom Manage 2003 ; 25, 5: 464-471.
1925 tidningen Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 tidningen Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1948 tidningen Classen AM, Wimbish GH, Kupiec TC.
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
J Pain Symptom Manage 2004 ; 28, 6: 603-611.
1953 tidningen Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964 tidningen Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1968 tidningen Williams OA, Middleton M, Henderson P, Reilly CS.
Stability of morphine and droperidol separately and combined, for use as an infusion.
Hosp Pharm Pract 1992 ; 2, 9: 597-600.
1974 tidningen Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982 tidningen Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2064 tidningen Nguyen-Xuan Tho, Griffiths W, Kern C, Van Gessel E, Bonnabry P.
Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management.
Int J Pharm Compound 2006 ; 10: 69-73.
2086 tidningen Sharley NA, Burgess NG.
Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes.
J Pharm Pract and Res 2003 ; 33: 279-281.
2108 tidningen Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2123 tidningen Lee G, Sabra K.
Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets.
EJHP Science 2006 ; 12, 4: 76-80.
2196 tidningen Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2233 tidningen Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 tidningen Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2251 tidningen Shields D, Montenegro R, Ragusa M.
Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration.
Neuromodulation 2005 ; 8, 4: 257-263.
2269 tidningen Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2298 tidningen Shields D.E, Aclan J, Szatkowski A.
Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration.
Int J Pharm Compound 2008 ; 12, 6: 553-557.
2305 tidningen Bianchi F, Ginggen A, Tardy Y.
Stability and compatibility of drug mixtures in an implantable infusion system.
Anaesthesia 2008 63, 9: 972-978.
2322 tidningen Donnelly R.F.
Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes.
Can J Hosp Pharm 2009 ; 62, 1
2350 tidningen Roy J.J, Hildgen P.
Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs.
Int J Pharm Compound 2000 ; 4, 3: 225-228.
3012 tidningen Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3131 tidningen Donnely RF, Wong K, Spencer J.
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl.
Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3152 tidningen Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184 Laboratorium
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3249 tidningen Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3279 tidningen Al-Tannak N.F, Cable C.G, McArthur D.A, Watson D.G
A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care.
J Clin Pharm Ther 2012 ; 37, 1: 71-73.
3434 tidningen Kistner C, Ensom M.H.H, Decarie D, Lauder G, Carr R.R.
Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection.
Can J Hosp Pharm 2013 ; 66, 3 : 167-170.
3474 Laboratorium Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3504 Laboratorium Parecoxib (Dynastat®) - Summary of Product Characteristics
Pfizer 2012
3507 Laboratorium Chirocaine - Summary of Product Characteristics
AbbVie 2013
3525 Laboratorium Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012
3531 Laboratorium Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3571 tidningen Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3578 Laboratorium Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3593 Laboratorium Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics
Beacon Pharmaceuticals 2011
3595 Laboratorium Aciclovir - Summary of Product Characteristics
Hospira 2009
3599 Laboratorium Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013
3644 Laboratorium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3675 Laboratorium Thiopental sodium - Summary of Product Characteristics
Archimedes Pharma UK Ltd 2015
3824 tidningen Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3828 affisch Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 affisch So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3934 Laboratorium Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
3948 tidningen Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 tidningen Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3998 tidningen Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C.
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.
Int J Pharm Compound 2017 ; 21:4 :347-351
4051 tidningen Robert J, Sorrieul J, Kieffer H, Folliard C, Gibory V, Dupoiron D, Devys C.
Stability study of morphine and baclofen solution in polypropylene syringes.
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:173-180
4055 tidningen Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 tidningen Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4303 tidningen Anderson C, MacKay M.
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Pharmacy 2015 3, 379-385.
4319 tidningen Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4380 Laboratorium Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4389 tidningen Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4395 affisch Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E.
Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C).
Sunnybrook Health Sciences Centre 2020
4419 tidningen Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434 tidningen Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4496 tidningen Sorrieul J, Robert J, Dupoiron D, Devys, C.
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.
Neuromodulation 2020 ; 24, 7: 1145-1156.
4528 tidningen Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4538 tidningen Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397.
4543 tidningen Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 tidningen Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratorium Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4669 tidningen Robert J, Sorrieul J, Dupoiron D, Jubier-Hamon S, Bienfait F, Visbecq A, Devys C.
Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration.
Neuromodulation 2021 : 1-16.
4730 tidningen Sorrieul J, Robert J, Vincent L, Andre M, Bourcier B, Bienfait F, Jubier Hamon S, Dupoiron D, Devys C.
Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures.
Neuromodulation 2022
4742 tidningen Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4801 tidningen Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
4837 tidningen De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales